Papillary thyroid cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Papillary thyroid cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Two Treatment Strategies for Intermediate-Risk Thyroid Cancer Using Sodium Iodide (131I) in Patients with Post-Surgery Evaluation https://clinicaltrials.eu/trial/study-comparing-two-treatment-strategies-for-intermediate-risk-thyroid-cancer-using-sodium-iodide-131i-in-patients-with-post-surgery-evaluation/ Wed, 29 Apr 2026 14:28:03 +0000 https://clinicaltrials.eu/trial/study-comparing-two-treatment-strategies-for-intermediate-risk-thyroid-cancer-using-sodium-iodide-131i-in-patients-with-post-surgery-evaluation/ This clinical trial is focused on studying a type of thyroid cancer known as intermediate-risk differentiated thyroid cancer. The trial is comparing two different strategies for using a treatment called radioiodine, which involves a substance known as sodium iodide (131I). This treatment is given in the form of capsules. The purpose of the study is to determine if a strategy guided by specific post-surgery tests is as effective as a standard approach in achieving a good response in patients.

Participants in the study will be randomly assigned to one of two groups. One group will receive radioiodine treatment based on a routine schedule, while the other group will have their treatment decisions guided by tests done after surgery. These tests include measuring a protein in the blood called thyroglobulin (Tg) and using a special imaging test called diagnostic RAI scintigraphy. The study will follow participants for several years to see how well each strategy works in treating the cancer.

The trial aims to assess the response to treatment at different time points, such as one, three, and five years after starting the study. It will also look at the quality of life, anxiety, and any side effects related to the treatment. The study will help determine if the guided approach can provide similar or better outcomes compared to the standard method, potentially leading to more personalized treatment plans for patients with this type of thyroid cancer.

]]> Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation https://clinicaltrials.eu/trial/study-on-selpercatinib-for-adults-with-advanced-or-metastatic-solid-tumors-with-ret-activation/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-on-selpercatinib-for-adults-with-advanced-or-metastatic-solid-tumors-with-ret-activation/ This clinical trial is focused on treating patients with certain types of advanced cancers, specifically those that have a change in a gene called Rearranged During Transfection (RET). The cancers being studied include Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, and other solid tumors with this specific gene change. The treatment being tested is a medication called selpercatinib, which is taken as a capsule by mouth.

The purpose of this study is to provide access to selpercatinib for patients who have these advanced cancers with the RET gene change. The study is designed to help patients who are not eligible for other ongoing clinical trials of selpercatinib. Participants will take the medication over a period of time, and their health will be monitored by their healthcare team. The study does not involve any specific data analysis or endpoints, meaning it is primarily focused on providing the treatment rather than collecting data for research purposes.

Patients who participate in this study will receive selpercatinib as part of an expanded access program, which is a way to provide treatment to patients who have no other options available. The treatment period can last up to 84 days, and the medication is taken orally. This study aims to support patients with advanced cancers by offering them a potential treatment option when other therapies are not suitable or available.

]]>